The Rabbit Polyclonal anti-KEAP1 antibody has been validated for WB, ELISA and IF. It is suitable to detect KEAP1 in samples from Human, Mouse and Rat.
Catalog No. ABIN6990770
Quick Overview for KEAP1 antibody (C-Term) (ABIN6990770)
At least two isoforms of KEAP1 are known to exist.
Purification
KEAP1 Antibody is affinity chromatography purified via peptide column.
Immunogen
Anti-KEAP1 antibody was raised against a 19 amino acid synthetic peptide near the carboxy terminus of human KEAP1. The immunogen is located within the last 50 amino acids of KEAP1.
Verified
KEAP1
Reactivity: Human
ELISA, IHC, IF
Host: Goat
Polyclonal
unconjugated
Application Notes
WB: 1-2 μ,g/mL, IF: 20 μ,g/mL.
Antibody validated: Western Blot in human, mouse and rat samples, Immunofluorescence in human samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
KEAP1 Antibody is supplied in PBS containing 0.02 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C,4 °C
Storage Comment
KEAP1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
KEAP1
(Kelch-Like ECH-Associated Protein 1 (KEAP1))
Alternative Name
KEAP1
Background
KEAP1 Antibody: KEAP1 (kelch-like ECH-associated protein 1) is a stress sensing adaptor for the Cullin3 (Cul3)-dependent E3 ubiquitin ligase complex that negatively regulates NRF2 (NF-E2-related factor 2) and plays a role in the oxidative stress response. It targets NFE2L2/NRF2 for ubiquitination and degradation by the proteasome. KEAP1 contains an amino terminal BTB/POZ domain and a carboxyl terminal KELCH domain which are required for interaction with NRF2, and in binding Cul3-E3 ubiquitin ligase. Altered expression of NRF2 is associated with chronic obstructive pulmonary disease (COPD). KEAP1 also targets the down regulation of NF-κ,B activity by targeting IKKβ, degradation. Mutation of the KEAP1 gene is found in lung cancer.